AbuT aiub Mohammed Mohiuddin Chowdhury

Dr. AbuT aiub Mohammed Mohiuddin Chowdhury


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
AbuT aiub Mohammed Mohiuddin ChowdhuryAbuT aiub Mohammed Mohiuddin Chowdhury
AbuT aiub Mohammed Mohiuddin Chowdhury
RKRezaul Karim
Rezaul Karim
AAAhasan Ali
Ahasan Ali
Jahirul IslamJahirul Islam
Jahirul Islam
YLYarui Li
Yarui Li
SHShuixiang He
Shuixiang He
Objective: Coronavirus disease 2019 (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a global issue. In addition to managing acute cases, post-COVID-19 persisting symptoms/complaints and different hematological values are of great concern. These have an impact on the patient's well-being and are yet to be evaluated. Therefore, clinical and primary diagnosis based on routine laboratory findings bears high importance during the initial period of COVID-19, especially in regions with fewer diagnostic facilities.Methods: Clinical information and associated complaints of the COVID-19 illness confirmed by reverse transcription-polymerase chain reaction (RT-PCR) were collected directly from the patients. Regular follow-ups were obtained on the phone every 2 weeks following recovery for 20 weeks. Initial hematological and radiology findings of the hospitalized patients except for intensive care unit (ICU) and high dependency units (HDUs) and a follow-up evaluation after 4 weeks following recovery were analyzed.Results: The post-COVID-19 persisting symptoms/complaints were found among 21.4% of symptomatic patients, which persisted for ≥20 weeks and had a significant relationship with the duration of COVID-19 illness and the existing comorbidity (p < 0.05). Post-COVID-19 primary type 2 diabetes mellitus (DM, 0.64%) and hypertension (HTN, 1.28%) and unstable DM (54.55%) and HTN (34.78%) to the pre-existing diabetic and hypertensive patients were observed. Post-recovery remarkable changes in the laboratory values included leukocytosis (16.1%), lymphocytosis (14.5%), and an increased prothrombin time (PT, 25.8%). Abnormalities in the D-dimer, serum ferritin, hemoglobin, and erythrocyte sedimentation rate (ESR) levels were present to an extent. Laboratory findings like chest X-ray, ESR, white blood cell (WBC) count, lymphocyte count, C-reactive protein (CRP), serum glutamic pyruvic transaminase (SGPT), serum ferritin, PT, D-dimer, and serum creatinine are important markers for the diagnosis and prognosis of COVID-19 illness (p < 0.05).Conclusion: Post-COVID-19 persisting symptoms and the changes in the laboratory values need to be considered with importance and as a routine clinical measure. Post-COVID-19 periodic follow-up for evaluating the patient's physical condition and the biochemical values should be scheduled with care and managed accordingly to prevent future comorbidity in patients with the post-COVID-19 syndrome.

25 February 2021 in Eurasian Journal of Medicine and Oncology
Verified
Journal Article
Closed access
PDF file
AbuT aiub Mohammed Mohiuddin ChowdhuryAbuT aiub Mohammed Mohiuddin Chowdhury
AbuT aiub Mohammed Mohiuddin Chowdhury
MSMohammad Shahbaz
Mohammad Shahbaz
MKMd. Rezaul Karim
Md. Rezaul Karim
Jahirul IslamJahirul Islam
Jahirul Islam
GDGuo Dan
Guo Dan
SHShuixiang He
Shuixiang He
Objectives: We investigated the outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy in mild to moderate COVID19 patients. Methods: Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for ten days in group A, and Hydroxychloroquine 400mg for the first day, then 200mg BID for nine days + Azithromycin 500mg daily for five days in group B (Control group). RT-PCR for SARS-CoV-2 infection was repeated in all symptomatic patients on the second day onward without symptoms. Repeat PCR was done every two days onward if the result found positive. Time to the negative PCR and symptomatic recovery was measured for each group. Results: All subjects in Group A reached a negative PCR, at a mean of 8.93 days, and reached symptomatic recovery, at a mean of 5.93 days, with 55.10% symptom-free by the fifth day. In group B, 96.36% reached a negative PCR at a mean of 9.33 days and were symptoms-free at 6.99 days. In group A 31.67% of patients expressed symptoms caused by medication, this was 46.43% in group B. Conclusion: The combination therapy of Ivermectin-Doxycycline showed a trend towards superiority to the combination of Hydroxychloroquine-Azithromycin for mild to moderate COVID19 disease.

5 April 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
AbuT aiub Mohammed Mohiuddin ChowdhuryAbuT aiub Mohammed Mohiuddin Chowdhury
AbuT aiub Mohammed Mohiuddin Chowdhury
AKAktar Kamal
Aktar Kamal
KAKafil Uddin Abbas
Kafil Uddin Abbas
STShubhashis Talukder
Shubhashis Talukder
RKRezaul Karim
Rezaul Karim
SHShuixiang He
Shuixiang He
Objective: In this study, we investigated the efficacy and safety of remdesivir and tocilizumab combination therapy against dexamethasone for the management of severe COVID-19 patients.Methods: This was a multicenter study. Cases were randomly chosen and divided into two groups using an odd–even ratio of 1:1 applied to the hospital registration number. Group A received remdesivir [5 mg/kg (40 kg) on day 1 and then 2.5 mg/kg (40 kg) daily] + tocilizumab [8 mg/kg up to 800 mg highest 12 h apart], and group B was the control and received dexamethasone 6 mg/day. In addition, a broad-spectrum antibiotic and other essential treatments were received by all patients. To evaluate the mortality risk, the sequential organ failure assessment (SOFA) score was calculated on day-1. Treatment outcomes were measured as time to clinical improvement; mortality rate; duration of ICU stay; total period of hospitalization; the rate of (Supplementary Material) oxygen use; time to clinical failure; National Early Warning Score-2 (NEWS), and the percentage of lung recovery on CT of chest on discharge. Clinical trial registration ID: NCT04678739.Results: Remdesivir-Tocilizumab group had a lower mortality rate (25.49%) than the control (30.77%). The time to clinical improvement (Group A-9.41; B-14.21 days), NEWS-2 on discharge (Group A-0.89; B-1.2), duration of ICU stay (Group A-7.68; B-10.58), and duration of hospitalization (Group A-9.91; B-14.68) were less in the treatment group. Group A had a better percentage of lung recovery on chest CT than the control (Group A-22.13; B-11.74). All these differences were statistically significant (p= <0.05) in a t-test. However, no significant survival benefit was found among the study groups in Kaplan–Meier survival analysis, p = 0.739.Conclusion: The remdesivir–tocilizumab combination had preferable outcomes compared to the dexamethasone therapy for the treatment of severe COVID-19 concerning mortality rate and clinical and pulmonary improvement, although it did not demonstrate a significant survival benefit.Clinical Trial Registration:https://clinicaltrials.gov, NCT04678739.

14 July 2020 in Research Square
Verified
Preprint
Open access
PDF file
AbuT aiub Mohammed Mohiuddin ChowdhuryAbuT aiub Mohammed Mohiuddin Chowdhury
AbuT aiub Mohammed Mohiuddin Chowdhury
MSMohammad Shahbaz
Mohammad Shahbaz
Md Rezaul KarimMd Rezaul Karim
Md Rezaul Karim
JIJohirul Islam
Johirul Islam
DGDan Guo
Dan Guo
SHShuixiang He
Shuixiang He
Background The worldwide COVID-19 pandemic was caused by a newly discovered Coronavirus. The treatment methods for COVID-19 are emerging and rapidly evolving. Existing drugs, including Ivermectin and Hydroxychloroquine, offer the hope of effective treatment in early disease. In this study, we investigated and compared outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy COVID19 patients with mild to moderate disease.Methods Patients with mild to moderate COVID-19 disease, tested positive by RT PCR for SARS-CoV-2 infection at Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh, were included in this study. Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100 mg BID for 10days in group A, and Hydroxychloroquine 400 mg 1st day, then200mg BID for 9days + Azithromycin 500 mg daily for 5 days in group B. PCR for SARS-CoV-2 was repeated in all symptomatic patients on the second day onward without symptoms, or, for those who were asymptomatic (throughout the process), on the 5th day after taking medication and repeated every two days onward if the result is positive. Time to negative PCR and time to full symptomatic recovery was measured for each group.Results All subjects in the Ivermectin-Doxycycline group (group A) reached a negative PCR for SARS-CoV-2, at a mean of 8.93days, and all reached symptomatic recovery, at a mean of 5.93days, with 55.10% symptom-free by the 5th day. In the Hydroxychloroquine-Azithromcyin group (group B), 96.36% reached a negative PCR at a mean of 6.99days and were symptoms-free at 9.33days. Group A patients had symptoms that could have been caused by the medication in 31.67% of patients, including lethargy in 14(23.3%), nausea in 11(18.3%), and occasional vertigo in 7(11.66%) of patients. In Group B, 46.43% had symptoms that could have been caused by the medication, including 13(23.21%) mild blurring of vision and headache; 22(39.2%) increased lethargy and dizziness, 10(17.85%) occasional palpitation, and 9(16.07%) nausea and vomiting.Conclusion The Ivermectin-Doxycycline combination showed a trend toward superiority to the Hydroxychloroquine-Azithromycin combination therapy in the case of patients with mild to moderate COVID19 disease, though the difference in time to becoming symptom-free and the difference in time to negative PCR was not statistically significant.

1 February 2020 in Translational Pediatrics
Verified
Journal Article
Open access
PDF file
AbuT aiub Mohammed Mohiuddin ChowdhuryAbuT aiub Mohammed Mohiuddin Chowdhury
AbuT aiub Mohammed Mohiuddin Chowdhury
YLYonglin Liu
Yonglin Liu
JLJuan Liu
Juan Liu
FJFuyong Jiao
Fuyong Jiao
GDGuo Dan
Guo Dan
SHShuixiang He
Shuixiang He
Appendicitis and convulsions are two common pathologies among children. Though appendicitis has some certain symptoms, they might present with atypical symptoms in young ages. Here we present a misleading case of a perforated appendix that presented with severe generalized convulsion, no significant abdominal symptoms and had a recent history of mild gastrointestinal problems. The primary symptoms and the related examination findings guided the differential diagnosis as viral encephalitis, febrile convulsion, and Epilepsy. The initial treatment was started accordingly with an aim to prevent further convulsion. But this case was later diagnosed as a case of peritonitis following perforated appendix and was operated successfully. After surgery, the patient recovered with no further attack of convulsion even following the postoperative withdrawal of sedative therapy. He was discharged on the 7th postoperative day and there were no major complaints on his follow-ups. Such misleading cases usually lead to misdiagnosis and might cause morbidity, even endanger the life of the patient. Therefore regarding children of sudden generalized convulsion with even minute abdominal findings or recent gastrointestinal history, it is necessary to pay attention and evaluate the abdomen by a CT or MRI besides the nervous system at the first impression.

1 April 2019 in Journal of Digestive Endoscopy
Verified
Journal Article
Open access
AbuT aiub Mohammed Mohiuddin ChowdhuryAbuT aiub Mohammed Mohiuddin Chowdhury
AbuT aiub Mohammed Mohiuddin Chowdhury
SHShuixiang He
Shuixiang He
RWRu Hua Wang
Ru Hua Wang
DGDan Guo
Dan Guo
YLYarui Li
Yarui Li
Gastric lesions presenting as polyps becomes common these days. Many different underlying causes have been suspected with the origin of gastric polyps. Generally, a gastric polyp is considered as benign in the first impression unless proven otherwise. Though, they show a vast variety of malignant potentials. This literature is intended to describe and evaluate the variations, presentations, features, and potentials of gastric polypoid lesions.